Press release
Fulcrum Therapeutics™ to Participate in Upcoming November Investor Conferences
CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving
About this update from Fulcrum Therapeutics, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will be participating in the following upcoming investor conferences: Credit Suisse 30th Annual Virtual Healthcare ConferenceThursday, November 11, 2021 at 4:20pm ET Stifel Virtual Healthcare ConferenceWednesday, November 17, 2021 at 11:20am ET Piper Sandler 33rd Annual Virtual Healthcare ConferenceTuesday, November 30, 2021. Webcast available beginning Monday, November 22, 2021 at 10:00am ET Live audio webcasts will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. Archived replays will be available on the Company’s website for 30 days. About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine, FulcrumSeek™, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. Fulcrum has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development. Please visit www.fulcrumtx.com. Contact:Naomi AokiSr. Vice President, Corporate Communications and Investor Relations [email protected] \nSource: Fulcrum Therapeutics, Inc.","length":3941,"tagName":"div"}]